Osaic Holdings
BCRX icon

Osaic Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

Osaic Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Buy
120,528
+45,059
+60% +$407K ﹤0.01% 2812
2026
Q1 		$718K Sell
75,469
-7,297
-9% -$56.7K ﹤0.01% 3009
2025
Q4 		$646K Buy
82,766
+21,011
+34% +$152K ﹤0.01% 3100
2025
Q3 		$470K Buy
61,755
+13,144
+27% +$109K ﹤0.01% 3478
2025
Q2 		$436K Buy
48,611
+4,466
+10% +$41.6K ﹤0.01% 3259
2025
Q1 		$331K Buy
44,145
+15,976
+57% +$129K ﹤0.01% 3219
2024
Q4 		$212K Buy
28,169
+14,953
+113% +$114K ﹤0.01% 3544
2024
Q3 		$100K Buy
13,216
+7,699
+140% +$58.5K ﹤0.01% 4218
2024
Q2 		$34.1K Sell
5,517
-745,177
-99% -$4.11M ﹤0.01% 4976
2024
Q1 		$3.81M Buy
750,694
+57,665
+8% +$324K 0.01% 1226
2023
Q4 		$4.15M Buy
693,029
+43,711
+7% +$253K 0.01% 1330
2023
Q3 		$4.6M Buy
649,318
+46,229
+8% +$332K 0.01% 1363
2023
Q2 		$4.25M Buy
603,089
+41,028
+7% +$329K 0.01% 1299
2023
Q1 		$4.69M Sell
562,061
-5,857
-1% -$56.4K 0.01% 1202
2022
Q4 		$6.52M Sell
567,918
-5,659
-1% -$70.6K 0.01% 943
2022
Q3 		$7.23M Sell
573,577
-13,230
-2% -$170K 0.02% 811
2022
Q2 		$6.21M Buy
586,807
+12,558
+2% +$130K 0.01% 912
2022
Q1 		$9.34M Buy
574,249
+13,750
+2% +$221K 0.02% 793
2021
Q4 		$7.76M Buy
560,499
+51,030
+10% +$675K 0.01% 868
2021
Q3 		$7.32M Buy
509,469
+93,624
+23% +$1.48M 0.02% 824
2021
Q2 		$6.58M Buy
415,845
+27,148
+7% +$369K 0.01% 885
2021
Q1 		$3.95M Buy
388,697
+73,863
+23% +$762K 0.01% 1100
2020
Q4 		$2.35M Buy
314,834
+150,241
+91% +$775K 0.01% 1320
2020
Q3 		$565K Buy
164,593
+65,746
+67% +$282K ﹤0.01% 2322
2020
Q2 		$471K Buy
98,847
+73,124
+284% +$292K ﹤0.01% 2394
2020
Q1 		$51K Buy
+25,723
New +$70.8K ﹤0.01% 3952

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Osaic Holdings's BCRX Position: Q2 2026 in Review

Osaic Holdings increased its BioCryst Pharmaceuticals (BCRX) stake by 60% in Q2 2026, buying an estimated $407K and bringing the position to 120,528 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2812.

Osaic Holdings first reported a position in BCRX in Q1 2020 and has held it in 26 quarters since. The position peaked at $9.34M in Q1 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Osaic Holdings held 120,528 shares of BioCryst Pharmaceuticals worth $1.21M as of Q2 2026.
  • Osaic Holdings bought 45,059 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $407K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #2812 holding.
  • Osaic Holdings first reported a position in BioCryst Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's BioCryst Pharmaceuticals position peaked at $9.34M in Q1 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.